FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Factor patents



      
           
This page is updated frequently with new Factor-related patent applications. Subscribe to the Factor RSS feed to automatically get the update: related Factor RSS feeds. RSS updates for this page: Factor RSS RSS


Date/App# patent app List of recent Factor-related patents
01/29/15
20150031748
 Modulating the interaction between zo-2/tjp2 and a snail zinc finger transcription factor family member patent thumbnailnew patent Modulating the interaction between zo-2/tjp2 and a snail zinc finger transcription factor family member
There is provided a method of identifying candidate agents capable of modulating interaction between a first polypeptide and a second polypeptide, wherein the first polypeptide is zo-2/tjp2 or a functional variant thereof and the second polypeptide is a snail zinc finger transcription factor family member or a functional variant thereof.. .
Agency For Science, Technology And Research
01/29/15
20150031747
 Methods and compositions for modulating factor vii expression patent thumbnailnew patent Methods and compositions for modulating factor vii expression
Disclosed herein are antisense compounds and methods for decreasing factor vii and treating, preventing, or slowing progression of thromboembolic complications, hyperproliferative disorders, or inflammatory conditions in an individual in need thereof.. .
Isis Pharmaceuticals, Inc.
01/29/15
20150031638
 Low anticoagulant heparins patent thumbnailnew patent Low anticoagulant heparins
The present invention relates to a chemically modified heparin, with an antifactor ii activity of less than 10 iu/mg, an antifactor xa activity of less than 10 iu/mg and an average molecular weight (mw) between about 6.5 and 9.5 kda. Also disclosed is a method of preparing the heparin and its medical use, including treatment of malaria..
Dilaforette Ab
01/29/15
20150031621
 Method for purification of complement factor h patent thumbnailnew patent Method for purification of complement factor h
E) followed by ultra/diafiltration to obtain a complement factor h concentrate.. .
01/29/15
20150031611
 Highly stabilized epidermal growth factor mutants patent thumbnailnew patent Highly stabilized epidermal growth factor mutants
There are provided mutants prepared by changing a dna base sequence and an amino acid sequence of an epidermal growth factor (egf), in which a mutant egf protein has excellent thermal stability and stability even in the state of an aqueous solution, and a gene encoding the protein are provided; a recombinant vector including the gene and a microorganism transformed by the recombinant vector are provided; a method of preparing the mutant egf protein is provided; a cosmetic composition for accelerating the growth of skin cell and skin regeneration, including the protein, the gene, or the recombinant vector, is provided; and by preparing a product using the egf mutant according to the present invention, it is possible to produce functional cosmetics, in which the activity thereof is maintained even during a distribution and storage process unlike the conventional wild-type egf product.. .
Pnp Biopharm Co., Ltd.
01/29/15
20150031516
 Lid for beverage container patent thumbnailnew patent Lid for beverage container
A lid for a beverage container is described. The lid has a basin that is designed to enhance the user's olfactory experience when drinking a beverage from the container and lid.
Harl-bella Holdings, Llc
01/29/15
20150031290
 Systems and methods for providing one or more functionalities to a wearable computing device with small form factor patent thumbnailnew patent Systems and methods for providing one or more functionalities to a wearable computing device with small form factor
A method substantially as shown and described in the detailed description and/or drawings and/or elsewhere herein. A device substantially as shown and described in the detailed description and/or drawings and/or elsewhere herein..
Elwha Llc
01/29/15
20150030688
 Honey and growth factor eluting scaffold for wound healing and tissue engineering patent thumbnailnew patent Honey and growth factor eluting scaffold for wound healing and tissue engineering
Tissue engineering structures with biologically favorable structural and chemical properties are disclosed. More particularly, the present disclosure is directed to tissue engineered scaffolds having a fiber support and honey.
Saint Louis University
01/29/15
20150030656
 Composition and  delivery of bmp-2 amplifier/co-activator for enhancement of osteogenesis patent thumbnailnew patent Composition and delivery of bmp-2 amplifier/co-activator for enhancement of osteogenesis
A composition comprising a synthetic growth factor analogue comprising a non-growth factor heparin binding region, a linker and a sequence that binds specifically to a cell surface receptor and an osteoconductive material where the synthetic growth factor analogue is attached to and can be released from the osteoconductive material and is an amplifier/co-activator of osteoinduction.. .
Biosurface Engineering Technologies, Inc.
01/29/15
20150030611
 Monitoring and modulating hgf/hgfr activity patent thumbnailnew patent Monitoring and modulating hgf/hgfr activity
Provided are methods and compositions for the modulation of hepatocyte growth factor activity to regulate lymphatic vessel development and function. Methods and composition for the monitoring and treatment of skin disorders, lymphedema, and metastatic cancers are disclosed.
The General Hospital Corporation
01/29/15
20150030597
new patent

Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer


The invention provides chimeric antigen receptors (cars) comprising an antigen binding domain of a kdr-1121 or dc101 antibody, an extracellular hinge domain, a t cell receptor transmembrane domain, and an intracellular domain t cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the cars are disclosed.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv
01/29/15
20150030534
new patent

Antibody cocktails for breast cancer radioimmunotherapy


The present invention provides compositions comprising a therapeutically effective combination of at least two of radionuclide-labeled anti-epidermal growth factor receptor (anti-egfr), radionuclide-labeled anti-cd-44, and radionuclide-labeled anti-cd-73. Or their respective antigen binding portions, and a pharmaceutically acceptable carrier, and method of use thereof for the treatment of breast cancer..
Rutgers, The State University Of New Jersey
01/29/15
20150030099
new patent

Circuits and methods for reducing the amplitude of complex signals


For crest factor reduction in a first signal having first and second components, the first component is delayed. A second signal is generated in response to detecting that a peak in the first component exceeds a predetermined threshold.
Texas Instruments Incorporated
01/22/15
20150026845

Compositions and related methods for modulating alkaloid production by controlling pmt promoter activation mediated by transcriptional factors erf and myc


Compositions and methods for modifying the production levels of alkaloids in plants are provided. Alkaloid production can be genetically controlled by modulating the transcriptional activation of pmt genes mediated by members of the erf family and/or myc family of transcription factors.
University Of Virginia Patent Foundation
01/22/15
20150026834

Anastasis biosensor


The present invention relates to the field of anastasis, i.e., the process of reversal of apoptosis. More specifically, the present invention provides methods and compositions useful for studying anastasis.
The Johns Kopkins University
01/22/15
20150026397

Method and system for providing memory module intercommunication


Exemplary embodiments include a memory module including a plurality of connectors, at least one memory, at least one transmitter and at least one receiver. The connectors are configured to fit with a form factor of a memory socket on a server board.
Samsung Electronics, Ltd.
01/22/15
20150025920

Check-in reduced carry on baggage system and other boarding process enhancements


A method for improving boarding of passengers and baggage onto a flight, comprises, at a predetermined time before the scheduled departure of the flight, determining an eligible carry-on baggage items count of carry-on baggage items eligible for treatment as checked baggage items. The eligible carry-on baggage items count is based on predetermined criteria comprising at least one of an aircraft type for the flight, a passenger load factor for the flight and carrier historical data relevant to the flight.
Alaska Airlines, Inc.
01/22/15
20150025096

Small molecule compounds to treat hearing loss


The invention is directed, in part, to compositions comprising small molecule compounds to treat or prevent hearing loss. Compositions of the present invention also promote sensory hair cell regeneration.
Fate Therapeutics, Inc.
01/22/15
20150025025

Immuno-modulators for treating functional epithelial syndromes


An immuno-modulating composition including an organic compound and a metal chelator or a metal ion. Also disclosed is a method for treating a disease or condition in man and animals with the composition.
01/22/15
20150025011

Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same


The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor xa inhibitor..
Portola Pharmaceuticals, Inc.
01/22/15
20150025010

Novel albumin-free factor viii formulations


A factor viii composition formulated without albumin, comprising the following formulation excipients in addition to factor viii: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mm to 5 mm calcium salt; 100 mm to 300 mm nacl; and a buffering agent for maintaining a ph of approximately between 6 and 8. Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mm to 5 mm calcium salt; 100 mm to 300 mm nacl; and a buffering agent for maintaining a ph of approximately between 6 and 8.
University Of Connecticut
01/22/15
20150024636

Electrical connector


An electrical connector to be connected with an next generation form factor (ngff) interface is disclosed, including a base, a plurality of first terminals, and a plurality of second terminals. A plurality of first terminal slots parallel disposed on one side of the base for the first terminals to be plugged thereinto.
Advanced-connectek Inc.
01/22/15
20150023982

Methods of administering anti-tnfalpha antibodies


Methods of treating disorders in which tnfα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (htnfα) are disclosed. The antibody may be administered with or without methotrexate.
Abbvie Biotechnology Ltd.
01/22/15
20150023959

Chimeric factor viii polypeptides and uses thereof


The present invention provides a vwf fragment comprising the d′ domain and d3 domain of vwf, a chimeric protein comprising the vwf fragment and a heterologous moiety, or a chimeric protein comprising the vwf fragment and a fviii protein and methods of using the same. A polypeptide chain comprising a vwf fragment of the invention binds to or is associated with a polypeptide chain comprising a fviii protein and the polypeptide chain comprising the vwf fragment can prevent or inhibit binding of endogenous vwf to the fviii protein.
Biogen Idec Ma Inc.
01/22/15
20150023947

Medicinal products for the treatment of blood coagulation disorders


A virally safe, thrombin-free factor-xia concentrate or a coagulation factor concentrate which contains factor xia as an active pharmaceutical ingredient and which is obtained by fractionation of plasma or serum or by genetic engineering and is suitable for the treatment of coagulation disorders attributable to diminished and/or delayed thrombin formation.. .
Bio-products & Bio-engineering Ag
01/22/15
20150023946

Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor viii


The present invention relates to pharmaceutical preparations comprising factor viii, a sulfated glycosaminoglycan and a hyaluronidase for the non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders. The invention further relates to the combined use of a factor viii, a sulfated glycosaminoglycan and a hyaluronidase for the treatment and prevention of bleeding disorders, and to a method for increasing the bioavailability after non-intravenous administration of factor viii by co-adminstration of a sulfated glycosaminoglycan and a hyaluronidase..
Csl Behring Gmbh
01/22/15
20150023507

Speaker protection in small form factor devices


An audio engine applies a driving signal to a speaker system, which produces an audio signal. The audio signal is captured by a microphone on the same device and feeds that signal back to the audio engine.
Nvidia Corporation
01/15/15
20150020010

Computer implemented methods and customizing a data interface in an on-demand service environment


Disclosed are methods, apparatus, systems, and computer program products for customizing a data interface in an on-demand service environment. In some implementations, a computing device provides an application for customizing a data interface displayable on a plurality of display devices having different form factors, the application providing one or more configurable templates.
Salesforce.com, Inc.
01/15/15
20150019257

System and predictive care management


Systems and methods for notifying clinicians of potential patient care risk scenarios and identifying remedial protocols to mitigate the risk. Patient data is downloaded from medical devices associated with the patient, such as, without limitation, a ventilator, bedside monitor, infusion pump, and/or dialysis machine.
Covidien Lp
01/15/15
20150018635

Multifactorial telehealth care pregnancy and birth monitoring


A system for monitoring a fetus in a pregnant woman, and/or the maternal health risk for pregnancies complicated by such as pre-eclampsia and hypertensive disorders is configured to be worn by the pregnant woman, preferably so as to allow monitoring during daily life, e.g. In the form of an adhesive patch.
Aalborg Universitet
01/15/15
20150018537

Process for perparing fondaparinux sodium and intermediates useful in the synthesis thereof


Processes for the synthesis of the factor xa anticoagulent fondaparinux, and related compounds are described. Also described are protected pentasaccharide intermediates as well as efficient and scalable processes for the industrial scale production of fondaparinux sodium by conversion of the protected pentasaccharide intermediates via a sequence of deprotection and sulfonation reactions..
Reliable Biopharmaceutical Corporation
01/15/15
20150018486

Nanotherapeutic colloidal metal compositions and methods


The present invention comprises compositions and methods for delivery systems of agents, including therapeutic compounds, pharmaceutical agents, drugs, detection agents, nucleic acid sequences and biological factors. In general, the nanotherapeutic compositions of the present invention comprise a platform comprising a colloidal metal, a targeting ligand such a tumor necrosis factor, a stealth agent such as polyethylene glycol, and one or more diagnostic or therapeutic agents for delivery.
Cytlmmune Sciences, Inc.
01/15/15
20150018406

Modulation of breast cancer growth by modulation of xbp1 activity


Described herein is a previously unknown function of xbp1 in triple-negative breast cancer (tnbc). It is shown that xbp1 is preferentially spliced and activated in tnbc, and that deletion of xbp1 significantly blocks triple negative breast tumor growth.
Cornell University
01/15/15
20150018305

Sirtuin inducer, tissue repairing agent, hepatocyte growth factor inducer, tissue homeostasis maintenance agent, and tlr4 agonist, having hyaluronic acid fragment as active ingredient


A hyaluronic acid fragment selected from sizes of 2 to 20 sugar units, a pharmaceutically acceptable salt thereof, or pharmaceutically acceptable solvates thereof, is employed as the active ingredient for the sirtuin inducer, tissue repairing agent, hepatocyte growth factor inducer, tissue homeostasis maintenance agent, or tlr4 agonist. The hyaluronic acid fragment is preferably selected from sizes of 3 to 10 sugar units, and more preferably selected from a size of 3 or 4 sugar unite..
01/15/15
20150018278

Phosphorylation on the thr-248 and/or thr-250 residues of transcription factor e2f4 as a therapeutic target in pathological processes associated with somatic polyploidy


The object of the invention is based on inhibiting specific phosphorylation on thr248 and/or thr250 residues of human transcription factor e2f4 to inhibit somatic endoreduplication processes in postmitotic cells which may be associated with various pathological conditions. The invention covers all currently known methods for the specific inhibition of protein phosphorylation (including the expression of mutant forms of e2f4 without thr residues phosphorylated by p38mapk) or methods developed in the future that may be applied to thr-248 and/or thr-250 residues of human transcription factor e2f4..
Consejo Superior De Investigaciones Cientificas (csic)
01/15/15
20150017724

Method for guiding the derivation of endothelial cells from human pluripotent stem cells employing two-dimensional, feeder-free differentiation


This invention relates, e.g., to a method for differentiating mammalian (e.g., human) pluripotent stem cells (pscs) into endothelial cells (ecs) in vitro, by plating a single-cell suspension of pscs onto a suitable surface such as type iv collagen and culturing the cells with vegf after which ecs can be harvested. A preferred embodiment of the method first cultures the cells without vegf and then sequentially cultures the cells with vegf.
The Johns Hopkins University
01/15/15
20150017720

Therapeutic uses of curcumin analogs for treatment of prostate cancer


This invention relates generally to methods of treating aggressive cancers, such as hormone-refractory metastatic prostate cancer, by exposing the aggressive cancer cells to curcumin analogs having the claimed structural scaffolds and side groups. The anticancer effects of curcumin are associated with its influence on numerous growth factors within the cells.
California State University Fresno
01/15/15
20150017547

Electrochemical devices based on block copolymers


The present invention relates generally to electrolyte materials. According to an embodiment, the present invention provides for a solid polymer electrolyte material that has high ionic conductivity and is mechanically robust.
Seeo, Inc
01/15/15
20150017263

Fn14 antagonists and therapeutic uses thereof


The present disclosure is directed to methods of using fibroblast growth factor-inducible 14 (fn14) antagonists to modulate activity at a tnf-like weak inducer of apoptosis (tweak) binding site on a cysteine-rich domain (crd) of fn14. The present disclosure also provides pharmaceutical compositions comprising synergistic combinations fn14 antagonists and chemotherapeutic agents..
The Translational Genomics Research Institute
01/15/15
20150017175

Methods of administering anti-tnfalpha antibodies


Methods of treating disorders in which tnfα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (htnfα) are disclosed. The antibody may be administered with or without methotrexate.
Abbvie Biotechnology Ltd.
01/15/15
20150017154

Anti-nerve growth factor antibodies and methods of preparing and using the same


A method of preparing an antibody suitable for use in a canine is provided. Also provided are caninised antibodies which specifically bind to canine neuronal growth factor (ngf) and neutralise the ability of canine ngf to bind to the p75 or trka canine ngf receptor.
Nvip Pty Ltd.
01/15/15
20150017134

Emt-inducing transcription factors cooperate with sox9


In some aspects, compositions and methods useful for generating stem cells from epithelial cells are disclosed.. .
Whitehead Institute For Biomedical Research
01/15/15
20150017118

Molded or extruded cork composite and manufacturing compressed cork pet products and pet toys made from the same


A cork-catnip composite material is provided that is capable of being molded, compressed, extruded or similarly processed into small or large bodies or sheets and allow for the economic manufacture of a variety of products for domestic pets, especially felines. Dried and granulated catnip (or similar olfactory attractant) is blended with a fill material such as powdered or granulated agglomerate cork material are then mixed with a bonding agent.
Ourpet's Company
01/15/15
20150016044

Socket interposer and computer system using the socket interposer


Exemplary embodiments include a socket interposer having a plurality of connectors and at least one of on-board memory and an external communication controller. The plurality of connectors is configured to fit with a form factor of a socket on a server board.
Samsung Electronics, Ltd.
01/15/15
20150015983

Size adjustable inter-track interference cancellation


Technologies are described herein for cancelling inter-track interference in a storage device utilizing size-adjustable segments. Data is read from one or more sectors on a data track adjacent to a target sector on a target track of a recording medium of the storage device.
Seagate Technology Llc
01/15/15
20150015384

Object detection device


An object of the present invention is to attain an object detection device that enables tracking travel control that does not cause a driver to experience a feeling of discomfort. An object detection device 104 of the present invention is an object detection device 104 that detects a subject 102 in front of the host vehicle on the basis of an image in which outside of the vehicle is captured from imaging devices 105 and 106 mounted in the host vehicle 103, and detects a relative distance or a relative speed with respect to the subject 102, having a risk factor determination unit 111 that, on the basis of the image, determines whether or not there is a risk factor that is a travel risk for the host vehicle 103..
Hitachi Automotive System, Ltd.
01/15/15
20150014421

Compact form factor integrated circuit card and methods


A compact form factor integrated circuit card. In one embodiment, a subscriber identity module (sim) card is disclosed.
Apple Inc.
01/15/15
20150014164

Analyte sensing device


Analyte sensing devices suitable for measuring ph or other analytes are provided in a variety of form factors, including a hand-held device.. .
Senova Systems, Inc.
01/15/15
20150013616

Molded or extruded catnip composite and manufacturing catnip pet toys and pet toys made from the same


A domestic pet toy is provided having a housing element formed of a moldable or extrudable catnip composite made of a solid catnip attractant, a lignocellulose cork agglomerate filler material, and an fda approved binding agent adhesive. The housing material provides sufficient delivery aromatic olfactory attractant to be effective in having an interactive response with a domestic feline.
Ourpet's Company
01/15/15
20150013331

Control internal combustion engine


A control apparatus for an internal combustion engine of the present invention switches a steady-state characteristic that defines a relation between an engine load factor and a throttle opening degree between a high atmospheric pressure steady-state characteristic and a low atmospheric pressure steady-state characteristic in accordance with whether or not the atmospheric pressure is higher than a predetermined value. According to the low atmospheric pressure steady-state characteristic, a throttle opening degree corresponding to an identical engine load factor is set to a smaller value compared to the high atmospheric pressure steady-state characteristic in a medium load region, and the throttle opening degree is set so as to increase as the engine load factor increases towards a full load in a region on the side of a higher load factor than the medium load region..
Toyota Jidosha Kabushiki Kaisha
01/08/15
20150013030

Plant transcriptional regulators


The invention relates to plant transcription factor polypeptides, polynucleotides that encode them, homologs from a variety of plant species, and methods of using the polynucleotides and polypeptides to produce transgenic plants having improved tolerance to drought, shade, and low nitrogen conditions, as compared to wild-type or reference plants.. .
Mendel Biotechnology, Inc.
01/08/15
20150012292

Warning system for infectious diseases and method therefor


A computer implemented method for predicting the local area impact of the spread of global infectious diseases including the steps of providing on a computer readable medium a global pathogen risk factors database having data stored therein related to local area vulnerability of a group of human pathogens across a plurality of areas, providing on a computer readable medium a global pathogen activity database having data stored therein related to the activity of the group of human pathogens in said plurality of geographies, providing on a computer readable medium a global transport database having data stored therein related to travel patterns in and/or between the plurality of areas, processing by a computer system data on each of the global pathogen risk factors database, the global pathogen activity database and the global transport database to generate a pathogen vulnerability index, a pathogen activity index and a transportability index, and processing by the computer system each of the pathogen vulnerability index, the pathogen activity index and the transportability index to generate a risk indicator indicative of the local area impact of individual global infectious diseases.. .
Biodiaspora Inc.


Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Factor for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Factor with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         





0.3567

3586

458899 - 0 - 72